Suppliers / Livzon Group Fuzhou Fuxing Pharmaceutical

Livzon Group Fuzhou Fuxing Pharmaceutical

China 16 employees Updated 9 July 2026

Livzon Group Fuzhou Fuxing Pharmaceutical is an API manufacturer based in China. It holds 15 active US drug master files and 14 valid CEPs across a filed portfolio of 17 molecules. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 5 April 2024 as NAI.

15
active US DMFs
14
valid CEPs
4
registered plants 1 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 5 April 2024 NAI US FDA
  • 3 August 2018 VAI US FDA
  • 20 March 2015 NAI US FDA
  • 11 November 2011 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Jiangyin, China Not on file
Fuzhou, China Not on file
Fujian, China Not on file
China, China 3006772356

What they file, and where

Molecule Regulators Docs
Colistimethate EDQM, SFDA (Saudi Arabia), US FDA 4
Tobramycin EDQM, US FDA 4
Vancomycin SFDA (Saudi Arabia), US FDA 4
Daptomycin SFDA (Saudi Arabia), US FDA 3
Teicoplanin EDQM, SFDA (Saudi Arabia) 3
Vancomycin Hydrochloride EDQM 3
Acarbose EDQM, US FDA 2
Milbemycin Oxime For Veterinary Use EDQM 2
Polymyxin B EDQM, US FDA 2
Colistin EDQM 1
Show all 17 molecules on file
Dalbavancin US FDA 1
Gentamicin US FDA 1
Kanamycin US FDA 1
Moxidectin US FDA 1
Moxidectin For Veterinary Use EDQM 1
Sirolimus US FDA 1
Telavancin US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 1 None
US FDA None 1
EMA None 1

Questions about Livzon Group Fuzhou Fuxing Pharmaceutical

Does Livzon Group Fuzhou Fuxing Pharmaceutical hold a US DMF or a CEP?
Livzon Group Fuzhou Fuxing Pharmaceutical holds 15 active US drug master files and 14 valid CEPs. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Livzon Group Fuzhou Fuxing Pharmaceutical FDA-registered?
One site operated by Livzon Group Fuzhou Fuxing Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Livzon Group Fuzhou Fuxing Pharmaceutical's last inspection go?
The most recent inspection on record closed on 5 April 2024 as NAI (No Action Indicated: nothing objectionable was found). 4 inspections are on file.
Where does Livzon Group Fuzhou Fuxing Pharmaceutical manufacture?
4 registered sites are on record, in China (Jiangyin, Fuzhou and Fujian among others). Every site is listed on this page with the register it came from.
What does Livzon Group Fuzhou Fuxing Pharmaceutical make?
17 molecules are on record against Livzon Group Fuzhou Fuxing Pharmaceutical, including Colistimethate, Tobramycin, Vancomycin and Daptomycin. Each links through to that molecule's full manufacturer list.
Which regulators recognise Livzon Group Fuzhou Fuxing Pharmaceutical's GMP?
Current GMP certificates are on record from US FDA and EMA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Livzon Group Fuzhou Fuxing Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 5 April 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates